BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34134574)

  • 1. A multicenter randomized phase II trial of hyperthermia combined with TPF induction chemotherapy compared with TPF induction chemotherapy in locally advanced resectable oral squamous cell carcinoma.
    Ren G; Ju H; Wu Y; Song H; Ma X; Ge M; Qiu W; Chen Y; He Y; Zhuang Q; Meng J; Guo W
    Int J Hyperthermia; 2021; 38(1):939-947. PubMed ID: 34134574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma.
    Zhong LP; Zhang CP; Ren GX; Guo W; William WN; Sun J; Zhu HG; Tu WY; Li J; Cai YL; Wang LZ; Fan XD; Wang ZH; Hu YJ; Ji T; Yang WJ; Ye WM; Li J; He Y; Wang YA; Xu LQ; Wang BS; Kies MS; Lee JJ; Myers JN; Zhang ZY
    J Clin Oncol; 2013 Feb; 31(6):744-51. PubMed ID: 23129742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A two-arm multicenter phase II trial of one cycle chemoselection split-dose docetaxel, cisplatin and 5-fluorouracil (TPF) induction chemotherapy before two cycles of split TPF followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer (TISOC-1).
    Inhestern J; Schmalenberg H; Dietz A; Rotter N; Maschmeyer G; Jungehülsing M; Grosse-Thie C; Kuhnt T; Görner M; Sudhoff H; Wittekindt C; Guntinas-Lichius O
    Ann Oncol; 2017 Aug; 28(8):1917-1922. PubMed ID: 28498880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term results of a randomized phase III trial of TPF induction chemotherapy followed by surgery and radiation in locally advanced oral squamous cell carcinoma.
    Zhong LP; Zhang CP; Ren GX; Guo W; William WN; Hong CS; Sun J; Zhu HG; Tu WY; Li J; Cai YL; Yin QM; Wang LZ; Wang ZH; Hu YJ; Ji T; Yang WJ; Ye WM; Li J; He Y; Wang YA; Xu LQ; Zhuang Z; Lee JJ; Myers JN; Zhang ZY
    Oncotarget; 2015 Jul; 6(21):18707-14. PubMed ID: 26124084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial.
    Hitt R; Iglesias L; López-Pousa A; Berrocal-Jaime A; Grau JJ; García-Girón C; Martínez-Trufero J; Guix M; Lambea-Sorrosal J; Del Barco-Morillo E; León-Vintró X; Cunquero-Tomas AJ; Baste N; Ocaña A; Cruz-Hernández JJ;
    Clin Transl Oncol; 2021 Apr; 23(4):764-772. PubMed ID: 32797376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective phase II randomized study of docetaxel combined with lobaplatin versus TPF regimen induction chemotherapy followed by concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma.
    Zhang M; Chen Y; Wu W; Jin F; Li Y; Long J; Luo X; Gong X; Chen X; Liu L; Tang H; Wang Z
    J Cancer Res Clin Oncol; 2023 Dec; 149(20):18081-18091. PubMed ID: 37985501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel, cisplatin and 5-FU compared with docetaxel, cisplatin and cetuximab as induction chemotherapy in advanced squamous cell carcinoma of the head and neck: Results of a randomised phase II AGMT trial.
    Keil F; Hartl M; Altorjai G; Berghold A; Riedl R; Pecherstorfer M; Mayrbäurl B; De Vries A; Schuster J; Hackl J; Füreder T; Melchardt T; Burian M; Greil R
    Eur J Cancer; 2021 Jul; 151():201-210. PubMed ID: 34022697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy With Cisplatin, 5-fluorouracil, ± Docetaxel for Larynx Preservation.
    Janoray G; Pointreau Y; Garaud P; Chapet S; Alfonsi M; Sire C; Jadaud E; Calais G
    J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26681800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 3 RCT comparing docetaxel-platinum with docetaxel-platinum-5FU as neoadjuvant chemotherapy in borderline resectable oral cancer.
    Noronha V; Patil V; Chaturvedi P; Mathrudev V; Menon N; Bhattacharjee A; Singh A; Peelay Z; Chakraborty S; Jadhav M; Alone M; Bhagyavant P; Kolkur M; Srinivas S; Das S; Roy S; Mandal T; Dsouza H; Saha S; Rai R; Srikanth A; Shah D; Khan A; Muthuluri H; Kumar A; Agarwal A; Rajpurohit A; Goli VB; Sekar A; Mantri A; Kanteti APK; Majumdar S; Khaddar S; Shenoy R; Elamarthi P; Rathnasamy N; Kashyap L; Abraham G; Booma N; Simha V; Chaukar D; Pai P; Nair S; Laskar S; Nawale K; Naidu P; Salian S; Shelar P; Raulo R; Dhumal SB; Prabhash K
    Eur J Cancer; 2024 Mar; 200():113560. PubMed ID: 38306841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The baseline oral microbiota predicts the response of locally advanced oral squamous cell carcinoma patients to induction chemotherapy: A prospective longitudinal study.
    Rui M; Zhang X; Huang J; Wei D; Li Z; Shao Z; Ju H; Ren G
    Radiother Oncol; 2021 Nov; 164():83-91. PubMed ID: 34571091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials.
    Budach W; Bölke E; Kammers K; Gerber PA; Orth K; Gripp S; Matuschek C
    Radiother Oncol; 2016 Feb; 118(2):238-43. PubMed ID: 26589131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Normal BMI predicts the survival benefits of inductive docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced oral squamous cell carcinoma.
    Zhao TC; Liang SY; Ju WT; Liu Y; Tan YR; Zhu DW; Zhang CP; Zhang ZY; Zhong LP
    Clin Nutr; 2020 Sep; 39(9):2751-2758. PubMed ID: 31839432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased Annexin A1 expression enhances sensitivity to docetaxel, cisplatin and 5-fluorouracil combination induction chemotherapy in oral squamous cell carcinoma.
    Sun W; Zhao T; Aladelusi TO; Ju W; Zhang Z; Zhong L; Zhu D
    J Oral Pathol Med; 2021 Sep; 50(8):795-802. PubMed ID: 34157171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck.
    Mesía R; Vázquez S; Grau JJ; García-Sáenz JA; Lozano A; García C; Carles J; Irigoyen A; Mañós M; García-Paredes B; del Barco E; Taberna M; Escobar Y; Cruz JJ;
    Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):289-96. PubMed ID: 26675064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer.
    Hitt R; Mesía R; Lozano A; Iglesias Docampo L; Grau JJ; Taberna M; Rubió-Casadevall J; Martínez-Trufero J; Morillo EDB; García Girón C; Vázquez Estévez S; Cirauqui B; Cruz-Hernández JJ
    Oral Oncol; 2022 Nov; 134():106087. PubMed ID: 36126605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of split-dose induction docetaxel, cisplatin, and 5-fluorouracil (TPF) chemotherapy followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer (TISOC-1).
    Oertel K; Spiegel K; Schmalenberg H; Dietz A; Maschmeyer G; Kuhnt T; Sudhoff H; Wendt TG; Guntinas-Lichius O
    BMC Cancer; 2012 Oct; 12():483. PubMed ID: 23083061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-dense TPF induction chemotherapy for locally advanced head and neck cancer: a phase II study.
    Hsieh CY; Lein MY; Yang SN; Wang YC; Lin YJ; Lin CY; Hua CH; Tsai MH; Lin CC
    BMC Cancer; 2020 Sep; 20(1):832. PubMed ID: 32873270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis.
    Kim R; Hahn S; Shin J; Ock CY; Kim M; Keam B; Kim TM; Kim DW; Heo DS
    Cancer Res Treat; 2016 Jul; 48(3):907-16. PubMed ID: 26582394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of incorporating cetuximab into docetaxel/cisplatin/fluorouracil induction chemotherapy and chemoradiotherapy for inoperable squamous cell carcinoma of the oral cavity: A phase II study.
    Chang PM; Lu HJ; Wang LW; Tai SK; Chen MH; Chu PY; Yang MH
    Head Neck; 2017 Jul; 39(7):1333-1342. PubMed ID: 28370774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323).
    van Herpen CM; Mauer ME; Mesia R; Degardin M; Jelic S; Coens C; Betka J; Bernier J; Remenar E; Stewart JS; Preiss JH; van den Weyngaert D; Bottomley A; Vermorken JB;
    Br J Cancer; 2010 Oct; 103(8):1173-81. PubMed ID: 20842129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.